Assertio Holdings, Inc. (NASDAQ:ASRT – Get Rating) CEO Daniel A. Peisert sold 26,391 shares of the firm’s stock in a transaction on Monday, April 11th. The stock was sold at an average price of $3.50, for a total value of $92,368.50. Following the sale, the chief executive officer now directly owns 158,402 shares in the company, valued at approximately $554,407. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.
Shares of NASDAQ:ASRT traded up $0.04 during trading on Wednesday, reaching $3.10. 1,338,018 shares of the stock were exchanged, compared to its average volume of 932,005. Assertio Holdings, Inc. has a 12 month low of $0.85 and a 12 month high of $3.52. The firm has a market cap of $140.53 million, a PE ratio of -155.00 and a beta of 1.54. The stock has a 50-day moving average price of $2.62 and a 200-day moving average price of $1.97. The company has a current ratio of 0.77, a quick ratio of 0.71 and a debt-to-equity ratio of 0.60.
Assertio (NASDAQ:ASRT – Get Rating) last released its earnings results on Wednesday, March 9th. The company reported $0.10 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.12 by ($0.02). Assertio had a negative net margin of 1.15% and a negative return on equity of 1.29%. During the same period in the prior year, the firm posted ($0.80) earnings per share. On average, sell-side analysts expect that Assertio Holdings, Inc. will post 0.35 earnings per share for the current fiscal year.
ASRT has been the topic of a number of recent research reports. Zacks Investment Research raised Assertio from a “hold” rating to a “buy” rating and set a $3.00 target price on the stock in a research report on Monday, February 21st. StockNews.com initiated coverage on Assertio in a report on Saturday, March 26th. They set a “buy” rating for the company.
About Assertio (Get Rating)
Assertio Holdings, Inc, a specialty pharmaceutical company, provides medicines in the areas of neurology, hospital, and pain and inflammation. Its pharmaceutical products include INDOCIN, an oral solution and a suppository form for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis.
Featured Stories
- Get a free copy of the StockNews.com research report on Assertio (ASRT)
- OrganiGram’s Turnaround Begins To Blossom
- Three Dividend Stocks With Growth Potential
- Exelon Stock Still Has Extraordinary Upside
- Ross Stores On The Verge Of Major Rally
- Insiders Are Selling Palo Alto Networks
Receive News & Ratings for Assertio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assertio and related companies with MarketBeat.com's FREE daily email newsletter.